News Conference News AHA 2017 RE-DUAL PCI Findings Consistent Across Key Subgroups Todd Neale November 16, 2017
Presentation AHA 2017 Cost Impact of Rivaroxaban Plus Aspirin versus Aspirin in the COMPASS Trial Presenter: Andre Lamy November 15, 2017
News Conference News AHA 2017 Aspirin Protective Against Early Death/MI in Prior PCI Patients Undergoing Noncardiac Surgery Shelley Wood November 14, 2017
News Conference News AHA 2017 GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS Yael L. Maxwell November 14, 2017
News Conference News AHA 2017 Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear Todd Neale November 14, 2017
News Conference News AHA 2017 Missed by Risk Calculators, Few Young MI Patients Were Previously on Statins Caitlin E. Cox November 14, 2017
Presentation AHA 2017 Subgroup Analysis from the RE-DUAL PCI Trial Presenter: Jonas Oldgren November 14, 2017
News Conference News AHA 2017 DACAB: Ticagrelor and Aspirin Improve SVG Patency at 1 Year Post-CABG vs Monotherapy Yael L. Maxwell November 12, 2017
News Conference News AHA 2017 Circling Back on ORBITA: Sham-Controlled PCI Trial Makes Best of 2017 List Michael O'Riordan November 12, 2017
Presentation AHA 2017 One-Year Outcomes: Prasugrel vs Ticagrelor in AMI Treated With PPCI PRAGUE-18 Study Presenter: Zuzana Motovska November 11, 2017
News Conference News AHA 2014 DAPT Study Shows Benefit of Long-Term Treatment After DES Implantation Yael L. Maxwell November 16, 2014